Table 3. Combined summary data for additional clinical trials with exenatide.

^LegendBID administration of exenetide in all studies with exenatide. Exen: exenatide. SU: sulfonylurea. MET: metformin. LAR: long-acting release. FPG: fasting plasma glucose. BIAsp: biphasic insulin aspart. BID: twice daily. ¹ 82 weeks; only included patients treated with exenatide [46, 47]. ² Overweight patients in all groups. 39% of patients who entered the extended study withdrew. No antibody results reported. Nausea reported from weeks 30-40 to weeks 70-82 [46]. ³ Overweight patients. 43% of patients who entered the extended study withdrew. No antibody results reported. Adverse effects reported from weeks 30-40 to weeks 70-82 [47]. ⁴ 16% of exenatide patients withdrew because of adverse events. Of the 115 (from 121 total) who were assessed, 40% were positive for anti-exenatide antibodies [49]. ⁵ 21.3% of patients withdrew from the exenatide arm vs. 10.1% from the insulin BIAsp 70/30 arm. 45% were positive for anti-exenatide antibodies [50]. ⁶ 19.4% of patients withdrew from the exenatide arm vs. 9.7% from the insulin glargine arm. 43% were positive for anti-exenatide antibodies [51]. ⁷ 67% were positive for anti-exenatide antibodies [52]. ⁸ Fraction of patients (in %) with HbA1c ≤ 7% at the end of the study. 9 Fraction of patients with adverse effects (in %). In some cases, where marked with an asterisk (^*), change of fraction of patients with adverse effects (in %) within the extended study (i.e. after completion of the first 30 wk study). ^a Cases (not percent). ^b Placebo-subtracted change. ^c Change treated patients vs. placebo. ^d Events per patient-year. ^e FPG reported as a 4 hour AUC in units of mmol/hr/l.